Blue Earth Therapeutics and University College London (UCL) have dosed the first participant in a Phase 1 clinical trial evaluating Actinium (²²⁵Ac) rhPSMA‑10.1 Injection in patients with metastatic castration‑resistant prostate cancer (mCRPC).
The UCL‑sponsored study, conducted at University College London Hospital, is assessing the safety and anti‑tumor activity of the investigational alpha‑emitting PSMA‑targeted radiopharmaceutical in patients with PSMA‑positive mCRPC whose disease has progressed after prior therapy. Blue Earth Therapeutics is supplying the study drug and funding the trial. The dose‑escalation design is intended to characterize side effects and inform dose selection for future studies.
Actinium‑225 is an alpha‑emitting radionuclide that delivers high‑energy radiation over very short tissue distances, causing irreparable DNA damage in targeted cancer cells while aiming to limit exposure to surrounding healthy tissue. Linked to the PSMA‑targeting molecule rhPSMA‑10.1, the construct is designed to deliver localized radiation directly to prostate cancer lesions.
Actinium (²²⁵Ac) rhPSMA‑10.1 is the second clinical candidate from Blue Earth Therapeutics’ oncology pipeline, alongside Lutetium (¹⁷⁷Lu) rhPSMA‑10.1 Injection, which is in a Phase 2 trial. Together, the programs reflect the company’s strategy to develop both alpha‑ and beta‑emitting radiopharmaceutical therapies using its radiohybrid PSMA platform.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!